Enzymotec Sets New 12-Month Low on Disappointing Earnings (ENZY)
Enzymotec (NASDAQ:ENZY)’s share price reached a new 52-week low on Tuesday following a dissappointing earnings announcement, American Banking and Market News reports. The company traded as low as $9.18 and last traded at $9.22, with a volume of 686,411 shares trading hands. The stock had previously closed at $14.98.
The company reported $0.02 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.10 by $0.08. The company had revenue of $11.50 million for the quarter, compared to the consensus estimate of $14.88 million. The company’s quarterly revenue was down 40.3% on a year-over-year basis.
Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of Enzymotec from an “underperform” rating to a “neutral” rating in a research note on Tuesday, July 15th. They now have a $15.20 price target on the stock. Separately, analysts at Jefferies Group cut their price target on shares of Enzymotec from $25.00 to $14.50 in a research note on Monday, May 19th. They now have a “hold” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Enzymotec presently has a consensus rating of “Hold” and a consensus target price of $19.93.
The stock has a 50-day moving average of $14.30 and a 200-day moving average of $19.87. The company has a market cap of $200.6 million and a price-to-earnings ratio of 23.59.
Enzymotec Ltd. is engaged in manufacturing of ingredients and medical foods company. Its technologies, research, and clinical validation process enables the Company to develop differentiated solutions across a variety of products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.